New Approaches to the therapy of sickle cell disease.
D000596:Amino Acids / Q000627:therapeutic use; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000986:Antisickling Agents / Q000627:therapeutic use; D002462:Cell Membrane / Q000187:drug effects; D003485:Cyanates / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D004913:Erythrocytes, Abnormal / Q000378:metabolism; D005319:Fetal Hemoglobin / Q000096:biosynthesis; D005985:Glyceraldehyde / Q000627:therapeutic use; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D007010:Hyponatremia / Q000503:physiopathology; D009842:Oligopeptides / Q000627:therapeutic use; D012995:Solubility; D012996:Solutions; D014508:Urea / Q000627:therapeutic use
D000596:Amino Acids; D000986:Antisickling Agents; D003485:Cyanates; D009842:Oligopeptides; D012996:Solutions; D006852:Hydrochlorothiazide; D005985:Glyceraldehyde; D014508:Urea; D005319:Fetal Hemoglobin; D003894:Deamino Arginine Vasopressin